On December 3, 2020 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") repoted that four abstracts detailing the Company’s clinical trials for Iomab-B and Actimab-A will be presented at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, which is being held virtually December 5-8, 2020 (Press release, Actinium Pharmaceuticals, DEC 3, 2020, View Source [SID1234572136]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Sandesh Seth, Actinium’s Chairman and CEO said "ASH is always a productive meeting for Actinium and we are excited that this year we have our largest presence ever with three oral presentations and a poster presentation. We are thrilled to have the opportunity to highlight the promising data from the pivotal phase 3 SIERRA trial for Iomab-B and our two Actimab-A combination trials with CLAG-M and venetoclax. Notably, we head into ASH (Free ASH Whitepaper) with a series of milestones expected for year-end and next year in addition to a strong cash position of $48 million at the end of the third quarter that will allow us to meet our development objectives well into 2022. We are also excited by recent developments in R&D and our recent senior hires that will enable us to succeed in achieving our near-term milestones and long-term vision for Actinium."
Mark Berger, Actinium’s Chief Medical officer, said, "We are pleased to present updated data from our Iomab-B pivotal Phase 3 SIERRA trial and Actimab-A combination trials this weekend at ASH (Free ASH Whitepaper). We are excited by the progress we have made across our pipeline and the strong potential our targeted radiotherapy agents have for improving the care of patients with relapsed or refractory AML. The data we will present at this year’s meeting is a reflection of the hard work done by our Actinium team and by our clinical sites to demonstrate the promise of our Antibody Radiation Conjugates. We would like to thank everyone for their contributions to this effort and we look forward to sharing the detailed presentations and updated data at this important meeting."
Iomab-B Oral Presentations Details:
Oral Presentation Title:
Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered
Publication Number:
193
Session Name:
721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities
Session Date:
Saturday, December 5, 2020
Presentation Time:
1:00 PM PT / 4:00 PM ET
Oral Presentation Title:
High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Publication Number:
135
Session Name:
721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities
Session Date:
Saturday, December 5, 2020
Presentation Time:
9:30 AM PT / 12:30 PM ET
Actimab-A CLAG-M Oral Presentation Details:
Oral Presentation Title:
A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML
Publication Number:
165
Session Name:
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Advances in immunotherapeutics for management of AML
Session Date:
Saturday, December 5, 2020
Presentation Time:
12:00 PM PT / 3:00 PM ET
Actimab-A Venetoclax Poster Presentation Details:
Poster Presentation Title:
Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study
Publication Number:
2875
Session Name:
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Session Date:
Monday, December 7, 2020
Presentation Time:
7:00 AM – 3:30 PM PT / 10:00 AM – 6:30 PM ET